Nimesulide : This newer NSAID is a relatively weak inhibitor of PG synthesis and there is some evidence to indicate relative COX2 selectivity. Anti-inflammatory action may be exerted by other mechanisms as well, e.g. reduced generation of superoxide by neutrophils, inhibition of PAF synthesis and TNFα release, free radical scavanging, inhibition of metalloproteinase activity in cartilage.
PREFERENTIAL COX2 INHIBITORS
This newer NSAID is a
relatively weak inhibitor of PG
synthesis and there is some evidence to indicate relative COX2 selectivity. Anti-inflammatory
action may be exerted by other mechanisms as well, e.g. reduced generation of
superoxide by neutrophils, inhibition of PAF synthesis and TNFα release, free radical
scavanging, inhibition of metalloproteinase activity in cartilage. The analgesic,
antipyretic and anti-inflammatory activity of nimesulide has been rated
comparable to other NSAIDs. It has been used primarily for shortlasting painful
inflammatory conditions like sports injuries, sinusitis and other earnosethroat
disorders, dental surgery, bursitis, low backache, dysmenorrhoea, postoperative
pain, osteoarthritis and for fever.
Nimesulide
is almost completely absorbed orally, 99% plasma protein bound, extensively metabolized
and excreted mainly in urine with a t½ of 2–5 hours.
Adverse effects of nimesulide are
gastrointestinal (epigastralgia, heart burn, nausea, loose motions),
dermatological (rash, pruritus) and central (somnolence, dizziness). Gastric
tolerability of nimesulide is better, though an Italian study has shown that ulcer
complications are as prevalent as with other NSAIDs. There is also no proof
that renal complications are missing: hematuria is reported in few children.
Instances of fulminant hepatic failure have been associated with nimesulide and
it has been withdrawn in Spain and Turkey; use in children is banned in
Portugal and Israel. However, a Finish committee for proprietary medicinal
products has concluded that hepatic reactions to nimesulide are similar to
other NSAIDs. Considering that it has not been marketed in many countries like
the UK, USA, Australia, Canada, the overall safety of this drug, especially in
children, has been questioned. However, most asthmatics and those who develop bronchospasm
or intolerance to aspirin and other NSAIDs do not cross react with nimesulide.
Its specific usefulness appears to be only in such patients.
Dose: 100 mg BD; NIMULID, NIMEGESIC,
NIMODOL 100 mg tab, 50 mg/5 ml
susp.
This
newer congener of piroxicam has a COX2/COX1
selectivity ratio of about 10. Since measurable inhibition of platelet TXA2
production (a COX1 function) occurs at therapeutic doses of meloxicam, it has
been labelled ‘preferential COX2 inhibitor’. Efficacy of meloxicam in osteo and
rheumatoid arthritis is comparable to piroxicam. In shortterm studies, gastric
changes with the lower dose (7.5 mg/day) were found to be similar to placebo, but
at the higher dose (15 mg/day) they were intermediate between placebo and
piroxicam. Gastric side effects of meloxicam are milder, but ulcer
complications (bleeding, perforation) have been reported on longterm use. Thus,
there is no convincing evidence that meloxicam is safer than other NSAIDs.
Dose: 7.5–15 mg OD; MELFLAM, MELOD, MUVIK,
MCAM 7.5 mg, 15 mg tabs.
It
is a prodrug—generates an active metabolite (6MNA),
and is a relatively more potent COX2 than COX1 inhibitor. It possesses analgesic,
antipyretic and anti-inflammatory activities; effective in the treatment of
rheumatoid and osteoarthritis as well as soft tissue injury. Nabumetone has
caused a lower incidence of gastric erosions, ulcers and bleeding, probably
because the active COX inhibitor is produced in tissues after absorption.
However, abdominal cramps and diarrhoea can occur and there is no firm evidence
of its relative safety compared to traditional NSAIDs.
NABUFLAM 500 mg tab; 1 tab OD.
Related Topics
TH 2019 - 2024 pharmacy180.com; Developed by Therithal info.